Skip to main content
The Journal of Clinical Endocrinology and Metabolism logoLink to The Journal of Clinical Endocrinology and Metabolism
. 2022 Jun 9;107(9):e3971. doi: 10.1210/clinem/dgac340

Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

PMCID: PMC9387686  PMID: 35679156

In the above-named article by Balasubramanian P, Wanner C, Ferreira JP, Ofstad AP, Elsaesser A, Zinman B, and Inzucchi SE (J Clin Endo Metab. 2022; doi: 10.1210/clinem/dgac154), a series of errors appeared in Table 1:

Some of the categorizations were missing in the first column. In the third row, “<65” should have been included. In the tenth row, “<25” should have been included. In the twenty-ninth row, “>1 to 5 years” should have been included. In the thirtieth row, “>5 years” should have been included. In the thirty-ninth row, “<30” should have been included.

The article has been corrected online.

The publisher acknowledges the errors.

doi: 10.1210/clinem/dgac154


Articles from The Journal of Clinical Endocrinology and Metabolism are provided here courtesy of The Endocrine Society

RESOURCES